• Advancing Retinal Gene Therapy with Atsena Therapeutics' Dr. Kenji Fujita

  • Mar 27 2025
  • Duración: 15 m
  • Podcast

Advancing Retinal Gene Therapy with Atsena Therapeutics' Dr. Kenji Fujita

Escúchala gratis

Ver detalles del espectáculo

  • Resumen

  • We love to hear from our listeners. Send us a message.

    In this episode of Cell & Gene: The Podcast, Host Erin Harris dives into the world of retinal gene therapy with Kenji Fujita, M.D., Chief Medical Officer of Atsena Therapeutics. Atsena develops treatments for inherited retinal diseases, including X-linked retinoschisis (XLRS), a rare genetic condition that currently has no FDA-approved therapy. They talk through the impact of XLRS on patients, the challenges of gene delivery to the retina, and how Atsena’s AAV vector technology is designed to overcome these hurdles. They also discuss the significance of the Fast Track designation recently granted to Atsena’s XLRS program, the role of patient advocacy in rare disease research, and the key milestones to watch for in the months ahead.

    Subscribe to the podcast!
    Apple | Spotify | YouTube
    Más Menos
Más Menos
adbl_web_global_use_to_activate_webcro768_stickypopup

Lo que los oyentes dicen sobre Advancing Retinal Gene Therapy with Atsena Therapeutics' Dr. Kenji Fujita

Calificaciones medias de los clientes

Reseñas - Selecciona las pestañas a continuación para cambiar el origen de las reseñas.

Reseñas de Audible.com

Opiniones de Amazon
No hay comentarios disponibles